Lisofylline

Lisofylline

SCHEMBL15423006

[2H]C([2H])([2H])n1c(=O)n(CCCC[C@@H](C)O)c(=O)c2c1ncn2C

nearest known ligand 0.86

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 6/20 0.59
TNF P01375 4/20 0.59
PDE4A P27815 2/20 0.59
PDE4B Q07343 2/20 0.59
PDE4C Q08493 2/20 0.59
PDE4D Q08499 2/20 0.59
USP2 O75604 1/20 0.59
LMNA P02545 1/20 0.59
CYP1A2 P05177 1/20 0.59
TSHR P16473 1/20 0.59
NFKB1 P19838 1/20 0.59
ACHE P22303 1/20 0.59
PMP22 Q01453 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
RXFP1 Q9HBX9 1/20 0.59
CHIT1 Q13231 1/20 0.51
CHIA Q9BZP6 1/20 0.51
AKR1B1 P15121 1/20 0.49
ADORA2A P29274 1/20 0.49
GLA P06280 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lisofylline SCHEMBL15341015 1.00 ADORA2B (0.59) ADORA2BTNFPDE4APDE4BPDE4C
Lisofylline SCHEMBL1495075 0.93 ADORA2B (0.59) ADORA2BTNFPDE4APDE4BPDE4C
Lisofylline, (S)- SCHEMBL1495100 0.93 ADORA2B (0.67) ADORA2BTNFPDE4APDE4BPDE4C
Lisofylline SCHEMBL39131 0.93 ADORA2B (0.67) ADORA2BTNFPDE4APDE4BPDE4C
Lisofylline SCHEMBL680306 0.93 ADORA2B (0.67) ADORA2BTNFPDE4APDE4BPDE4C
Lisofylline SCHEMBL15423044 0.92 ADORA2B (0.58) ADORA2BTNFPDE4APDE4BPDE4C
Lisofylline SCHEMBL15341010 0.92 ADORA2B (0.58) ADORA2BTNFPDE4APDE4BPDE4C
SCHEMBL8700060 0.92 ADORA2B (0.66) ADORA2BTNFPDE4APDE4BPDE4C
SCHEMBL8699282 0.92 ADORA2B (0.66) ADORA2BTNFPDE4APDE4BPDE4C
SCHEMBL6778919 0.92 ADORA2B (0.66) ADORA2BTNFPDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9085788-B2 Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation CONCERT PHARMACEUTICALS, INC. (US) 2015-07-21 US disclosed
US-20140017739-A1 PROCESS FOR PREPARING AN ENANTIOMERICALLY ENRICHED, DEUTERATED SECONDARY ALCOHOL FROM A CORRESPONDING KETONE WITHOUT REDUCING DEUTERIUM INCORPORATION CONCERT PHARMACEUTICALS, INC. (US) 2014-01-16 US disclosed